Neridronic acid molecular complex for treating complex regional pain syndrome

1. A molecular complex comprising neridronic acid in an acid or a salt form and an amino acid in an acid, a base, or a salt form, wherein the amino acid is alanine, arginine, asparagine, aspartic acid, cysteine, selenocysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.

2. The molecular complex of claim 1 , wherein the amino acid is an L-amino acid.

3. The molecular complex of claim 1 , wherein the amino acid is a D-amino acid.

4. The molecular complex of claim 1 , wherein the amino acid is a DL-amino acid.

5. The molecular complex of claim 1 , wherein the amino acid is alanine, isoleucine, leucine, methionine, proline, or valine.

6. The molecular complex of claim 1 , wherein the amino acid is histidine or arginine.

7. The molecular complex of claim 1 , wherein the amino acid is aspartic acid or glutamic acid.

8. The molecular complex of claim 1 , wherein the amino acid is phenylalanine, tyrosine, or tryptophan.

9. The molecular complex of claim 1 , wherein the amino acid is asparagine, glutamine, serine, threonine, cysteine, or selenocysteine.

10. A method of treating complex regional pain syndrome comprising, administering a molecular complex comprising neridronic acid in an acid or a salt form and an amino acid in an acid, a base, or a salt form to a human being suffering from complex regional pain syndrome, wherein the amino acid is alanine, arginine, asparagine, aspartic acid, cysteine, selenocysteine, glycine, glutamic acid, glutamine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.

11. The method of claim 10 , wherein the amino acid is a DL-amino acid.

12. The method of claim 10 , wherein the amino acid is a D-amino acid.

13. The method of claim 10 , wherein the amino acid is an L amino acid.

14. The method of claim 10 , wherein the complex regional pain syndrome is complex regional pain syndrome type I.

15. The method of claim 10 , wherein the complex regional pain syndrome is complex regional pain syndrome type II.

16. The method of claim 10 , wherein the molecular complex is administered about every three months, or more frequently.

17. The method of claim 10 , wherein the human being experiences pain relief at least 24 hours after the molecular complex is administered to the human being.

18. The method of claim 10 , wherein the human being experiences pain relief three months after the molecular complex is administered.

19. The method of claim 10 , wherein the human being experiences pain relief that lasts for a duration of at least 48 hours after administration of the molecular complex.

20. The method of claim 10 , wherein there is a period of about 24 hours to about 7 days between instances of administration of the molecular complex.

21. The method of claim 10 , wherein the molecular complex is administered weekly.

22. The method of claim 10 , wherein there is a period of about 7 days to about 14 days between instances of administration of the molecular complex.

23. The method of claim 10 , wherein there is a period of about 14 days to about 28 days between instances of administration of the molecular complex.

24. The method of claim 10 , wherein there is a period of at least one month between instances of administration of the molecular complex.

25. The method of claim 10 , wherein the molecular complex is administered more than once.

26. The method of claim 10 , wherein the molecular complex is administered in an amount that results in an AUC of neridronic acid, measured over the entire course of treatment, of about 30,000 ng·h/mL to about 100,000 ng·h/mL.

27. The method of claim 10 , wherein the molecular complex is administered in an amount that results in an AUC of neridronic acid, measured over the entire course of treatment, of about 30,000 ng·h/mL to about 50,000 ng·h/mL.

28. The method of claim 10 , wherein the molecular complex is administered in an amount that results in an AUC of neridronic acid, measured over the entire course of treatment, of about 50,000 ng·h/mL to about 70,000 ng·h/mL.

29. The method of claim 10 , wherein the molecular complex is administered in an amount that results in an AUC of neridronic acid, measured over the entire course of treatment, of about 70,000 ng·h/mL to about 100,000 ng·h/mL.

30. The method of claim 10 , wherein the molecular complex is administered orally.